CClinicalTrials.gg
CompletedNCT00000286Updated Jan 12, 2017

Effects of Nefazodone on Treatment of Female Cocaine Abusers - 3

A Phase 2 interventional study of Nefazodone in Cocaine-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA). Completed at 1 site in United States. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-01-12.

Sponsored by National Institute on Drug Abuse (NIDA) · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
0
Ages
18 Years to 55 Years
Sex
Female
01

Study summary

The purpose of this study is to determine the effects of nefazedone on cocaine self-administration in depressed and non-depressed female cocaine users.

Read the detailed description

This study evaluated the effect of nefazodone on reducing cocaine use and craving in both depressed and nondepressed women and if there was a greater effect in depressed women.

02

Conditions studied

  • Cocaine-Related Disorders

Keywords

  • cocaine dependence
03

In context

Cocaine-Related Disorders

415 studies on the registry are indexed under Cocaine-Related Disorders; 12 are open to participants now.

Browse Cocaine-Related Disorders studies →

Lead sponsor

National Institute on Drug Abuse (NIDA) is the lead sponsor of 388 studies on the registry; 19 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 5 (42%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

Females, ages 18-55, minimum use of 8 days of the last 30, minimum of 8th grade education, current diagnosis of cocaine abuse/dependence

Exclusion criteria

Exclusion Criteria:

Unstable medical illness, dx of MR, OBS, bipolar

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Masking
Double
Enrollment
0 participants

Interventions

  • DrugNefazodone
06

What researchers measure

Primary outcomes

  1. Craving

  2. Drug use

  3. Depression

  4. Life functioning

  5. HIV risk behaviors

07

Study locations

1 site
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00000286
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
University of Minnesota
First posted
Sep 21, 1999
Start date
Dec 1996
Completion
Dec 2001
Last update
Jan 12, 2017

Study contacts

Dorothy Hatsukami, Ph.D.
principal investigator · University of Minnesota
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion